Moderna shares jump, set for eight straight day of gains

** Shares of Moderna MRNA rise 9.8% to $157.79, on track for their eight straight session of advances, if gains hold; other vaccine stocks also climb

** Jefferies analyst Michael Yee points to Australia's first human case of avian influenza in a child who authorities said had been infected in India but made a full recovery

** Citizens JMP analyst Roy Buchanan, who covers CureVac, says that if the H5N1 strain of bird flu becomes a greater concern, there will be interest in accelerating bird flu vaccine programs as happened with COVID-19

** Shares of Moderna MRNA up ~10%, Novavax NVAX up ~12.4% and CureVac CVAC up ~27.4%

** BioNTech (BNTX.0) rise ~8.3%, while Pfizer PFE up 2%

** Including session's move, stock of CVAC and BNTX down 1% to 4%, MRNA up ~58.6%, PFE up ~1.2% and NVAX shares have more than tripled YTD